Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH) (ARAMIS)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Low dose of Micardis®
Medium dose of Micardis®
High dose of Micardis®
Hydrochlorothiazide
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- At least 35 years, but less than 85 years of age
- Mean SBP ≥ 150 mm Hg and mean DBP < 90 mm Hg at the randomisation visit (visit 2), according to WHO definitions of ISH (excluding the subgroup of borderline ISH)
- Hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient (investigator's discretion)
- Ability to provide written informed consent
Exclusion Criteria:
Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:
- are not surgically sterile; and/or
- are nursing
- are of child-bearing potential and are not practicing acceptable means of birth control or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives
- Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2
- Known or suspected secondary hypertension
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- Serum glutamic pyruvate transaminase (ALT) or serum glutamic oxaloacetic transaminase (AST) > than 2 times the upper limit of normal range
- Serum creatinine > or 1.8 mg/dl (or 159 µmol/l)
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney
- Clinically relevant hypokalemia or hyperkalemia
- Uncorrected volume or sodium depletion
- Primary aldosteronism
- Hereditary fructose intolerance
- Biliary obstructive disorders
- Symptomatic congestive heart failure
- Angina pectoris or previous myocardial infarction
- Previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft
- Previous cerebrovascular accident or hypertensive encephalopathy or transient ischemic attack(s)
- Current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out
- Atrial fibrillation (controlled or otherwise) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator
- Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle
Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history:
- Fasting blood glucose less than 200 mg/dl (11.1 mmol/l)
- Therapy stabilized for at least one month prior to start of placebo run-period
- Patients with diabetes mellitus requiring treatment with insulin
- Patients who have previously experienced symptoms characteristics of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
- Known drug or alcohol dependency
- Any investigational therapy within one month of signing the informed consent form and during the trial
- Known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides
- Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
- Gout (contraindication for treatment with HCTZ)
- Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
Arm Label
Low dose of Micardis®
Medium dose of Micardis®
High dose of Micardis®
Hydrochlorothiazide
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)
Change from baseline in urine albumine excretion rate
Change from baseline in pulse wave velocity
Secondary Outcome Measures
Percentage of patients achieving a target fall in SBP
Changes in seated diastolic blood pressure (DBP)
Change from baseline in augmentation index
Incidence and intensity of adverse events
Number of patients with relevant changes from baseline in physical examination
Number of patients with relevant changes in Heart Rate (HR)
Number of patients with relevant changes in laboratory parameters
Number of patients with relevant changes in 12-lead electrocardiogram (ECG)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02175355
Brief Title
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
Acronym
ARAMIS
Official Title
A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
October 1999 (undefined)
Primary Completion Date
August 2000 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Primary: To identify doses of Micardis®(telmisartan) which, administered once daily, are more effective than placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH), and to assess the dose response relationship of the antihypertensive effect of telmisartan over the dose range of 20 to 80 mg.
Secondary: Target fall in SBP, change from baseline in seated DBP. Safety and tolerability of Micardis® and HCTZ in patients with ISH as measured by changes in physical examinations, heart rate, laboratory parameters and/or 12-lead ECG, as well as the incidence and severity of adverse events.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1039 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low dose of Micardis®
Arm Type
Experimental
Arm Title
Medium dose of Micardis®
Arm Type
Experimental
Arm Title
High dose of Micardis®
Arm Type
Experimental
Arm Title
Hydrochlorothiazide
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Low dose of Micardis®
Intervention Type
Drug
Intervention Name(s)
Medium dose of Micardis®
Intervention Type
Drug
Intervention Name(s)
High dose of Micardis®
Intervention Type
Drug
Intervention Name(s)
Hydrochlorothiazide
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)
Time Frame
after 6 weeks of treatment
Title
Change from baseline in urine albumine excretion rate
Time Frame
after 6 weeks of treatment
Title
Change from baseline in pulse wave velocity
Time Frame
after 6 weeks of treatment
Secondary Outcome Measure Information:
Title
Percentage of patients achieving a target fall in SBP
Time Frame
after 6 weeks of treatment
Title
Changes in seated diastolic blood pressure (DBP)
Time Frame
up to 6 weeks
Title
Change from baseline in augmentation index
Time Frame
after 6 weeks of treatment
Title
Incidence and intensity of adverse events
Time Frame
up to 6 weeks
Title
Number of patients with relevant changes from baseline in physical examination
Time Frame
baseline, week 6
Title
Number of patients with relevant changes in Heart Rate (HR)
Time Frame
up to 6 weeks
Title
Number of patients with relevant changes in laboratory parameters
Time Frame
up to 6 weeks
Title
Number of patients with relevant changes in 12-lead electrocardiogram (ECG)
Time Frame
up to 6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
84 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
At least 35 years, but less than 85 years of age
Mean SBP ≥ 150 mm Hg and mean DBP < 90 mm Hg at the randomisation visit (visit 2), according to WHO definitions of ISH (excluding the subgroup of borderline ISH)
Hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient (investigator's discretion)
Ability to provide written informed consent
Exclusion Criteria:
Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:
are not surgically sterile; and/or
are nursing
are of child-bearing potential and are not practicing acceptable means of birth control or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives
Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2
Known or suspected secondary hypertension
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
Serum glutamic pyruvate transaminase (ALT) or serum glutamic oxaloacetic transaminase (AST) > than 2 times the upper limit of normal range
Serum creatinine > or 1.8 mg/dl (or 159 µmol/l)
Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney
Clinically relevant hypokalemia or hyperkalemia
Uncorrected volume or sodium depletion
Primary aldosteronism
Hereditary fructose intolerance
Biliary obstructive disorders
Symptomatic congestive heart failure
Angina pectoris or previous myocardial infarction
Previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft
Previous cerebrovascular accident or hypertensive encephalopathy or transient ischemic attack(s)
Current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out
Atrial fibrillation (controlled or otherwise) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator
Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle
Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history:
Fasting blood glucose less than 200 mg/dl (11.1 mmol/l)
Therapy stabilized for at least one month prior to start of placebo run-period
Patients with diabetes mellitus requiring treatment with insulin
Patients who have previously experienced symptoms characteristics of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
Known drug or alcohol dependency
Any investigational therapy within one month of signing the informed consent form and during the trial
Known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides
Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
Gout (contraindication for treatment with HCTZ)
Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.254_U01-1348.pdf
Description
Related Info
Learn more about this trial
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
We'll reach out to this number within 24 hrs